878 Novel microbial immunotherapy approach for the treatment of bladder cancer

医学 膀胱癌 免疫疗法 癌症 流式细胞术 碘化丙啶 泌尿科 免疫系统 内科学 肿瘤科 癌症研究 免疫学 细胞凋亡 程序性细胞死亡 生物 生物化学
作者
Nicholas Glanville,Tobi A. Oke,Sonia Domingos‐Pereira,Lenka Polák,Denise Nardelli‐Haefliger,Livija Deban
出处
期刊: 卷期号:: A920-A920 被引量:1
标识
DOI:10.1136/jitc-2021-sitc2021.878
摘要

Background

Microbial immunotherapy, in the form of intravesical Bacillus Calmette-Guérin (BCG), is the standard-of-care for non-muscle invasive bladder cancer (NMIBC). BCG therapy is associated with significant side-effects, high disease recurrence and progression rates, and product supply shortages, leaving a significant unmet medical need for bladder cancer patients.1 2 We sought to establish the preclinical safety and efficacy of live-attenuated Salmonella enterica Typhi strain ZH9 (ΔaroC, ΔssaV) as a novel microbial immunotherapy.

Methods

Therapeutic efficacy of intravesical ZH9 was established in the murine orthotopic, syngeneic MB49 bladder tumor model. Tumor-bearing animals were treated with a single intravesical dose of ZH9 or OncoTice BCG and long-term survival comparisons were evaluated by log-rank (Mantel-Cox) test. ZH9 interaction with urothelial cancer cells was investigated using in vitro invasion assays and flow cytometry staining for intracellular Salmonella common antigen (CSA-1) and propidium iodide for cell death. Local immune responses were analyzed by flow cytometry staining of disaggregated mouse bladders.

Results

Mice treated with a single intravesical dose of ZH9 2 days after MB49 tumor inoculation demonstrated significant survival benefit compared to vehicle treated (median survival 49.5 vs. 31 days, p=0.003) and BCG treated animals (median survival 49.5 vs. 27.5 days, p<0.001). A second, stringent model setup with intravesical treatment 4 days after tumor inoculation showed significant efficacy of ZH9 versus vehicle and BCG (median survival 30 vs. 20.5 (p=0.003) and 23.5 (p=0.025) days, respectively). Surviving ZH9 treated animals demonstrated 100% protection from tumor take following repeated intravesical challenge with MB49 tumor cells, suggesting lasting anti-tumor immunity resulting from ZH9 treatment. In vitro, intracellular flow cytometry in human (UMUC3, T24, RT4, 5637) and mouse (MB49) urothelial cancer cell lines showed that ZH9 invaded and induced cell death in all cell lines. In vivo, a single treatment with intravesical ZH9 resulted in strong cellular immune responses characterized by recruitment of monocytes, NK cells, CD4+ and CD8+ T cells, and dendritic cells with an activated, cross-presenting (Ly6C+, CD103+) phenotype. Intravesical ZH9 resulted in a greater magnitude and duration of immune cell recruitment in the urothelium compared to a single equivalent dose of intravesical BCG.

Conclusions

Live-attenuated Salmonella strain ZH9 demonstrated a significant survival benefit over the standard-of-care OncoTice BCG in an orthotopic bladder cancer model. ZH9 demonstrated direct tumour cell killing in vitro and induction of robust cellular immune responses in vivo. Preclinical studies indicate significant therapeutic potential of intravesical ZH9 as a novel microbial immunotherapy in bladder cancer.

References

Liu Y, Lu J, Huang Y, Ma L. Clinical spectrum of complications induced by intravesical immunotherapy of Bacillus Calmette-Guérin for bladder cancer. J Oncol 2019 March 10;2019:6230409. vanRhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009 September;56(3):430–42.

Ethics Approval

The studies were conducted under approval from Pennsylvania State College of Medicine Institutional Animal Care and Use Committee approval number 47682, or with approval of the Cantonal Veterinary Office of Canton de Vaud, Switzerland.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
neurospine发布了新的文献求助10
刚刚
li发布了新的文献求助10
1秒前
3秒前
4秒前
远了个方发布了新的文献求助10
4秒前
5秒前
远了个方发布了新的文献求助10
5秒前
远了个方发布了新的文献求助10
5秒前
5秒前
李爱国的应助被外向烨磊采纳,获得10
6秒前
Jasper的应助被DYY采纳,获得10
6秒前
隐形曼青的应助被neurospine采纳,获得10
7秒前
FashionBoy的应助被Liam采纳,获得10
8秒前
9秒前
李健的小迷弟的应助被taik采纳,获得10
9秒前
整齐芷文完成签到,获得积分10
10秒前
Justin完成签到,获得积分10
11秒前
夏夏发布了新的文献求助10
12秒前
12秒前
cube发布了新的文献求助10
14秒前
xz完成签到,获得积分10
16秒前
16秒前
16秒前
neurospine完成签到,获得积分10
16秒前
16秒前
远了个方发布了新的文献求助10
17秒前
司藤完成签到 ,获得积分0
18秒前
18秒前
19秒前
20秒前
Chen发布了新的文献求助10
21秒前
23秒前
ZX发布了新的文献求助10
23秒前
23秒前
24秒前
24秒前
25秒前
25秒前
风清扬的应助被tantan采纳,获得10
25秒前
N你好发布了新的文献求助10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192903
求助须知:如何正确求助?哪些是违规求助? 9579346
关于积分的说明 21864636
捐赠科研通 7792529
什么是DOI,文献DOI怎么找? 3437107
关于科研通互助平台的介绍 2560653
邀请新用户注册赠送积分活动 2483937